Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06175000 · ClinicalTrials.gov registry record · Phase 2
Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
A Phase 2 study of Primary Central Nervous System Lymphoma, sponsored by Providence Health & Services.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 7
- Study locations
NCT06175000: Recruiting Phase 2 study of Primary Central Nervous System Lymphoma, sponsored by Providence Health & Services.
NCT06175000 is a Phase 2 study of Primary Central Nervous System Lymphoma that is actively recruiting participants, run by Providence Health & Services. The registered enrollment target is 28 participants, below the 50-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (44% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06175000, a Phase 2 study of Primary Central Nervous System Lymphoma, is actively recruiting participants, sponsored by Providence Health & Services.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 7
- Study locations
Study Summary
This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment (partial response). Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread.
Primary Outcome
PR or CR duration will be assessed using Kaplan-Meier product limit estimates and compared between patients with maintenance versus without obinutuzumab maintenance using the log-rank test. In addition, the Cox proportional hazard model will be used to estimate hazard ratios.
Conditions Studied
Interventions
- PROCEDURE Cognitive Assessment
- BIOLOGICAL Obinutuzumab
- OTHER Quality of Life Assessment
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic - Cleveland
Oregon
- Providence Health & Services; Providence Neurological Specialties - Portland
Pennsylvania
- Pennsylvania State University - Hershey
Vermont
- University of Vermont - Burlington
Virginia
- University of Virginia - Charlottesville
Washington
- Ivy Center for Advanced Brain Tumor Treatment; Swedish Neuroscience Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-03-13 |
| Est. Completion | 2029-09-15 |
| Phase | Phase 2 |
What NCT06175000 shows while recruiting
NCT06175000 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 50-participant average among 12 other Primary Central Nervous System Lymphoma trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Primary Central Nervous System Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cognitive Assessment is the first listed.
NCT06175000 lists 7 locations in 7 states (New York, Ohio, Oregon).
Frequently Asked Questions
What is clinical trial NCT06175000 about?
NCT06175000 is a clinical study titled "Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response". This randomized phase II trial studies how well obinutuzumab works as maintenance treatment in patients with central nervous system lymphoma who have achieved the disappearance of all signs of cancer in response to treatment (complete response) or a decrease in the size of a tumor, or in the extent ...
What is the current status of trial NCT06175000?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2024-03-13. Estimated completion is 2029-09-15.
What conditions does trial NCT06175000 study?
This clinical trial studies the following conditions: Primary Central Nervous System Lymphoma.
What interventions are being tested in trial NCT06175000?
The interventions under investigation include: Cognitive Assessment (PROCEDURE), Obinutuzumab (BIOLOGICAL), Quality of Life Assessment (OTHER).
Who is sponsoring clinical trial NCT06175000?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06175000 being conducted?
This trial has 7 study locations across New York, Ohio, Oregon, Pennsylvania, Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Central Nervous System Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06175000's enrollment target sits among peer trials
28 6th of 12 higher than 7 of 12 other Primary Central Nervous System Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Central Nervous System Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
RECRUITING · Phase 2
-
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
RECRUITING · Phase 2
-
Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)
COMPLETED · Phase 2
-
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
RECRUITING · Phase 1
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI